Domenica Lorusso, MD, PhD, on Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer
ESMO Congress 2026
Domenica Lorusso, MD, PhD, of Humanitas University, summarizes findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 study, which showed sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate, provided statistically significant and clinically meaningful improvements in progression-free and overall survival and response vs treatment of physician’s choice in patients with previously treated advanced or recurrent endometrial cancer, with manageable safety (Abstract LBA11).
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial carcinoma (Abstract LBA12).
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center—a co-chair of a Presidential Symposium at the ESMO Congress 2026—reviews results from the phase III trial that looked at the CLDN18.2-targeting antibody-drug conjugate sonesitatug vedotin vs investigator’s choice of therapy after at least one prior therapy for gastroesophageal cancer expressing CLDN18.2 in ≥ 25% tumor cells with membranous staining at any intensity (Abstract LBA7).
Sanjiv S. Gangaram-Panday, PhD, of Erasmus University, presents 5-year outcomes from the Surgery As Needed for Oesophageal Cancer (SANO) trial. The study previously demonstrated that active surveillance is noninferior to standard surgery in terms of 2-year overall survival in patients with a complete clinical response after neoadjuvant chemoradiotherapy; active surveillance also resulted in improved quality of life (Abstract LBA78).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, reviews results from the phase III G-HOPE-001 trial, which evaluated the CLDN18.2-targeted antibody-drug conjugate arcotatug tavatecan in previously treated patients with gastric or gastroesophageal junction (GEJ) cancer. Dr. Smyth was a co-chair of the proffered paper session that featured the abstract (Abstract LBA77).
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses data from the phase III KEYNOTE-975 study, which examined definitive chemoradiotherapy with or without pembrolizumab in patients with previously untreated locally advanced unresectable esophageal and gastroesophageal junction (GEJ) cancer. Dr. Smyth was a co-chair of the proffered paper session that featured the abstract (Abstract 2875O).
